News | Intravascular Imaging | December 15, 2021

Conavi Will Commercialize Intravascular Image Guidance Technology With $20 Million in Funding

First clinical system that co-registers IVUS and OCT

The Conavi Novasight hybrid intravascular imaging system that combines IVUS and OCT.

The Conavi Novasight hybrid intravascular imaging system that combines IVUS and OCT.


December 15, 2021 — Conavi Medical Inc. has entered into agreements for over $20 million in funding to support commercialization and growth as it prepares its innovative Novasight Hybrid System for market. The company aims to raise an additional $10 million as part of an ongoing financing effort.  

The Novasight Hybrid System for interventional cardiology is used during common minimally invasive heart procedures. The technology is the first clinical system that enables simultaneous and co-registered imaging of coronary arteries with both intravascular ultrasound (IVUS) and optical coherence tomography (OCT). The Novasight Hybrid System was recently featured as part of a live case performed by New York Presbyterian Hospital and broadcast during the TCT 2021 conference.

“This transformational funding is a testament to the potential the Novasight Hybrid System has on a global scale. It provides the company with the runway to reach important operational and commercial milestones as we drive the value proposition of this innovative system,” said Thomas Looby, Conavi Medical CEO.

Angioplasty and stenting are performed over 4 million times around the world every year as an important part of the treatment of coronary artery disease, including patients suffering from heart attacks and angina. Recent randomized studies with existing IVUS systems have shown that intravascular imaging has the potential to significantly improve clinical outcomes during angioplasty and stenting.

The Conavi Novasight hybrid intravascular imaging system that combines IVUS and OCT.“By combining the two most commonly used imaging modalities - ultrasound and OCT - our system provides a comprehensive assessment of coronary arteries, which is useful for determining the size of the artery as well as both the nature and extent of the plaque” said Dr. Brian Courtney, chief medical officer and co-founder, Conavi Medical. “A number of studies from around the world are consistently demonstrating that intravascular imaging improves procedural results in percutaneous coronary interventions (PCI) and its use is growing. Hybrid imaging with IVUS and OCT will play an important role in this growth through its synergistic versatility in a wide range of coronary interventions and potential for greater ease and consistency of interpretation.”
  
Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration (FDA), and regulatory approval for clinical use from Health Canada, and the Ministry of Health, Labor and Welfare (MHLW) in Japan.

For more information: http://www.conavi.com/
 

Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now